New York’s proposed Beauty Justice Act would materially change how cosmetics and personal care companies assess ingredient restrictions, supplier documentation, retailer assurances, and litigation exposure in the state. The proposal gained renewed attention after the New York Senate passed S.2057B on April 21, 2026, by a 51–11 vote and delivered it to the Assembly the following day. The companion bill, A.2054B, remains before the Assembly Ways and Means Committee.
The legislation has not become law. Still, its scope warrants attention because the current version would restrict dozens of substances in cosmetics and personal care products while imposing obligations that extend beyond formulation. The bill defines manufacturers broadly, creates a certificate-of-compliance system for retailers, and establishes daily civil penalties. Those provisions could also influence private consumer litigation where product claims, ingredient disclosures, or compliance representations are challenged.
Beauty Justice Act Ingredient Restrictions Could Reshape Cosmetics Formulation
The Beauty Justice Act is one of the more expansive state proposals addressing chemicals used in cosmetics and personal care products. The current B version would prohibit, beginning January 1, 2030, the sale or offer for sale in New York of covered products containing a listed restricted substance as an intentionally added ingredient. It also directs the New York Department of Environmental Conservation to establish the lowest feasibly achievable level for certain substances, including lead, and revisit those thresholds over time.
The restricted list covers numerous substances and chemical classes, including certain heavy metals, PFAS, parabens, formaldehyde-related substances, benzophenones, siloxanes, phenylenediamines, triclosan, and other ingredients used across the personal care sector. The definition of an intentionally added ingredient also reaches components of fragrances, flavorings, and colorants when those components continue to serve a functional or technical purpose in the finished product.
For manufacturers, the practical effect could extend beyond the ingredient statement printed on packaging. Companies may need better visibility into fragrance systems, color preparations, raw material specifications, and supplier disclosures. Product portfolio management could therefore require a deeper review of formulation records and upstream sourcing information.
The proposal would operate alongside the federal Modernization of Cosmetics Regulation Act of 2022 (MoCRA), which expanded FDA oversight through facility registration, product listing, adverse-event reporting, safety substantiation, and related requirements. MoCRA still leaves room for states to restrict cosmetic ingredients, which means national brands may have to manage state-specific ingredient rules separately from federal obligations.
Cosmetics Brands May Face New Supplier, Retailer, and Certification Obligations
One of the bill’s more consequential provisions is its definition of manufacturer. The term would include a business that produces, prepares, formulates, or compounds a personal care product, but it would also include a business whose brand name appears on the product. For imported products, the importer or first domestic distributor can also fall within the definition when the foreign manufacturer or brand owner lacks a U.S. presence.
For brands using contract manufacturers, that definition makes contractual allocation of responsibility more important. A brand owner could face direct statutory exposure even when another company controls sourcing, formulation, manufacturing, or testing. Agreements with formulators and manufacturers may therefore need clearer provisions addressing ingredient disclosure, testing rights, change control, warranties, and indemnification.
The bill would also allow retailers to rely in good faith on a manufacturer’s written certificate of compliance confirming that a product satisfies the Act. That certificate must be signed by an authorized manufacturer representative, and issuing one for a noncompliant product would itself constitute a violation.
This could affect retailer onboarding and vendor-management practices. Retailers may respond by requesting certificates, supporting test results, supplier warranties, audit rights, and reimbursement protections before accepting products for sale in New York.
Beauty Justice Act Litigation Risk Could Extend Beyond State Enforcement
The statutory penalties are relatively clear. A violation could result in a civil penalty of up to $1,000 per day, increasing to as much as $2,500 per day for a second violation. Courts could also enjoin continued violations.
The broader litigation concern is less direct. Plaintiffs may attempt to use an alleged Beauty Justice Act violation to support consumer-fraud, false-advertising, toxic-exposure, or product-liability theories, depending on the facts of a particular case. The Act would therefore matter even where enforcement begins with state regulators rather than private plaintiffs.
The overlooked issue is product representation risk. A brand that markets a product as “clean,” “non-toxic,” “safe,” “free from” certain chemicals, or compliant with ingredient restrictions may face greater exposure if testing later identifies a restricted substance. Written retailer certifications could also become evidence in discovery, turning a formulation issue into a broader advertising and consumer-protection dispute.
Industry opposition has focused heavily on this point. On June 1, 2026, the Personal Care Products Council and a coalition of brands, retailers, cosmetic chemists, and small businesses opposed S.2057B/A.2054B, arguing that the proposal could affect products containing trace substances that occur naturally in materials such as clay, mineral pigments, and water. On June 4, 2026, PCPC separately criticized the bill’s scientific basis and potential impact on common products including shampoo, deodorant, and sunscreen.
strategic by design: The Juris Law Group Perspective
The Beauty Justice Act should be viewed as a combined formulation, contracting, and advertising issue. As consumer products and manufacturing attorneys in California, we assess how state ingredient restrictions affect national product portfolios, manufacturer agreements, retailer requirements, and consumer-facing claims.
The practical focus should be on whether supplier controls, testing records, contractual protections, and marketing statements all tell the same story. Our approach reflects a simple principle: Bigger is not better, better is better®. For cosmetics companies, better documentation and better control over product representations can matter more than adding layers of process that do not reduce exposure.
Beauty Justice Act Compliance Planning Should Begin Before the Bill Becomes Law
Over the next 12 months, attention will remain on whether the Assembly advances A.2054B, revises the restricted-substance provisions, changes the proposed January 1, 2030 sales restriction, or modifies DEC’s authority over trace levels. The legislation has now advanced through the Senate in consecutive legislative cycles, so cosmetics companies with New York distribution should continue monitoring it even though it is not yet enforceable law.
More broadly, New York’s proposal reflects continued movement toward state-level cosmetics ingredient controls alongside MoCRA. For national brands, the most restrictive large-market jurisdiction can end up influencing formulation, sourcing, retailer contracting, and advertising decisions across the country. Companies with disciplined supplier records, defensible product claims, and clear manufacturing agreements will be in a stronger position if New York or other states adopt broader ingredient restrictions.
Common Legal Inquiries
Has the New York Beauty Justice Act become law?
No. As of August 25, 2026, S.2057B has passed the New York Senate, but the companion legislation remains in the Assembly. The proposed restrictions are therefore not currently enforceable.
When would the Beauty Justice Act cosmetics restrictions take effect?
Under the current B version, the principal sales restrictions would begin January 1, 2030. The proposal also contemplates earlier agency work on safer alternatives and implementing standards.
Could a cosmetics brand be liable if a contract manufacturer makes the product?
Potentially. The bill’s proposed definition of manufacturer includes a business whose brand name appears on the product. That makes supplier disclosures, testing rights, manufacturing agreements, warranties, and indemnification provisions especially important for private-label and contract-manufactured products.
